Keyphrases
Chronic Kidney Disease
100%
Patients with Diabetes
100%
Diabetic Kidney Disease
100%
Sotagliflozin
100%
Confidence Interval
50%
Placebo
50%
Hazard Ratio
50%
Heart Failure Hospitalization
37%
Placebo Groups
25%
Heart Failure
25%
Albuminuria
25%
First Occurrence
25%
Type 2 Diabetic Patients
12%
Low Risk
12%
Type 2 Diabetes Mellitus (T2DM)
12%
Lexicon
12%
Cardiovascular Events
12%
Diabetic Ketoacidosis
12%
Death Rate
12%
Adverse Events
12%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
12%
Nonfatal Myocardial Infarction
12%
Glycated Hemoglobin Levels
12%
Nonfatal Stroke
12%
Estimated Glomerular Filtration Rate
12%
Body Surface Area
12%
Number of Deaths
12%
Diarrhea
12%
Sanofi
12%
Risk for Cardiovascular Diseases
12%
Double-blind Trial
12%
Volume Depletion
12%
Genital Mycotic Infection
12%
Medicine and Dentistry
Patient with Diabetes
100%
Chronic Kidney Disease
100%
Sotagliflozin
100%
Placebo
75%
Cardiovascular System
75%
Congestive Heart Failure
62%
Hazard Ratio
50%
Albuminuria
25%
Maturity Onset Diabetes of the Young
12%
Adverse Event
12%
Myocardial Infarction
12%
Cardiovascular Disease
12%
Apoplexy
12%
Patient with Type 2 Diabetes
12%
Glycated Hemoglobin
12%
Diabetic Ketoacidosis
12%
Mycosis
12%
Sodium Glucose Cotransporter 2 Inhibitor
12%
Glomerular Filtration Rate
12%
Diarrhea
12%
Body Surface
12%
Pharmacology, Toxicology and Pharmaceutical Science
Chronic Kidney Failure
100%
Sotagliflozin
100%
Placebo
75%
Congestive Heart Failure
62%
Albuminuria
25%
Adverse Event
12%
Non Insulin Dependent Diabetes Mellitus
12%
Cardiovascular Disease
12%
Heart Infarction
12%
Diabetic Ketoacidosis
12%
Glycosylated Hemoglobin
12%
Cerebrovascular Accident
12%
Mycosis
12%
Diarrhea
12%
sodium glucose cotransporter-2 inhibitors
12%